Latest news with #DividendAristocrats
Globe and Mail
17-05-2025
- Business
- Globe and Mail
3 Oversold Dividend Aristocrats Wall Street Says Are Ready to Rally
Thanks to improving geopolitical sentiment, the markets are breathing some fresh green air—and that means some investors try to time the market and race to buy. Elevated trade volumes can mean higher stock prices, which can be difficult for the smart money to justify. However, not every dividend stock has bounced back. Some are still trading at oversold or near-oversold prices while maintaining positive upward momentum with room for growth. Finding quality names, such as companies on the Dividend Aristocrats list, can be a smart way to build long-term wealth and steady returns. So, today, let's look at oversold, Wall-Street-approved Dividend Aristocrats on a potential uptrend. How I Came Up With The Following Oversold Dividend Aristocrats With Barchart's Stock Screener, I screened for stocks on the Dividend Aristocrats list using the following filters: 100-200D MA Cross Signal: Buy. This filter looks for stocks with their 100-day moving average (MA100) above their 200-day moving average (MA200). This crossover is considered a strong bullish signal, indicating that the stock's medium-term momentum is shifting upwards and potentially entering or continuing a long-term uptrend. Overall Buy/Sell/Hold Signal: Buy. This filter takes all Barchart Opinion indicators and gives an overall rating based on 13 popular analytics in short-, medium- and long-term periods. Current Analyst Rating: 4 (Moderate Buy) to 5 (Strong Buy). 14-Day Relative Strength Index: Left blank. This filter maps out the stock's price movement on a 100-point scale based on the last 14 days of trading, with 80 and above being the overbought level and 30 and below oversold. Watchlists: Aristocrats. With these filters in place, I ran the screen and got seven results: Then, I arranged the results based on the lowest to highest 14-day RSI. The combination of the 100-200 MA Cross Signal, the overall buy rating based on Barchart Opinion and Wall Street, and the relatively low RSI (below 50) may suggest that the stock has just bounced from a downtrend and is starting an upward trend. Furthermore, I'll limit the results to stocks currently trading above their 100-MA line, which thankfully applies to all top three companies. Now, let's discuss each, starting with the one with the lowest 14-day RSI. Coca-Cola Company (KO) Pretty much everyone knows about the Coca-Cola Company. In terms of market cap, it's considered the largest beverage company on Earth. The giant reaches more than 200 countries with 2.2 billion daily drink sales. Currently, Coca-Cola has hundreds of bottling partners across 950 production facilities worldwide. It's also one of the most popular dividend stocks, being a member of the Dividend Aristocrats, Kings, and Zombie dividend lists, and is generally considered a cornerstone income investment due to its non-cyclical products. Coke pays a $0.51 per quarter dividend, which translates to a forward yield of around 2.8%. Certainly not the highest there is, but Coca-Cola offers stable income - which is what long-term investors want. After staying below the 200-day MA line for a couple of months, KO's 100-day MA line has finally crossed above, marking a potential jumping point for a longer uptrend. Abbott Laboratories (ABT) Next on the list is Abbott Laboratories, another well-known dividend stock. The company develops, produces, and markets healthcare products ranging from medical devices to brand medicines and nutritional products. As of now, Abbott has increased its dividends for 53 consecutive years. Abbott currently pays $2.36 annually, which reflects around a 1.7% yield. Analysts give ABT stock a strong buy rating. Up about 17.5% YTD, ABT stock is also doing well, though we saw some of the same price drops during tariff announcements. However, it's still trading above its 100-day MA and has shown signs of recovery, which suggests further upward momentum. McDonald's Corp (MCD) Last on this list is McDonald's Corporation, another global brand with a dominant presence in the fast food industry. Contrary to popular belief, McDonald's doesn't just operate as a franchise fast food join - it's also a real estate business. The company owns a sizable portion of its land and buildings, which serves as an excellent source of revenue. Combined with its business in the consumer staples sector, MCD stock is one of the more recession-proof investments available. The company pays a $1.77 quarterly dividend, which translates to $7.08 annually and around a 2.2% yield. MCD stock's price is also above its 100-day MA, though its 200-day MA is closing in. This can suggest a sign of potential weakness in the price action, especially when considering its mostly sideways pattern as of late, so investors will want to watch out for further downward pressure or increased selling volume. Final Thoughts These oversold Dividend Aristocrats offer the opportunity to buy quality stocks at low prices and benefit from their anticipated upward climb. However, nothing stays still in the stock market. Particularly, values like the 14-day RSI can change drastically in one trading session. So it's essential always to monitor your investments and do your due diligence before buying anything.
Globe and Mail
16-05-2025
- Business
- Globe and Mail
Dividend Aristocrats Offer Safety in Market Storms. Buy These 2 Top-Rated Stocks Now.
Dividend Aristocrats, firms with over 25 years of annual dividend growth, show their resilience through recessions, periods of sticky inflation, and market downturns, rewarding investors with reliable income and long-term stability. These stocks are battle-tested shelters, and two compelling options right now could be Coca-Cola (KO) a beverage titan, and West Pharmaceutical Services (WST), a key player in drug delivery systems. Both stocks have decades of dividend growth behind them and solid momentum ahead. To that end, investors should consider grabbing these top-rated defensive gems now. Dividend Aristocrat Stock #1: Coca-Cola Valued at a market cap of $296 billion, the beverage stock is up 9.6% over the past 52 weeks and 11.1% in 2025 alone. Even when the markets wobble, Wall Street keeps betting on its timeless charm – Coke just keeps bubbling to the top. Coca-Cola is not just refreshing thirst, it is refreshing portfolios. KO, a proud Dividend King, has raised its dividend for 63 straight years, proving loyalty to its investors. In 2024 alone, it poured out $8.4 billion in dividends, pushing total payouts since 2010 to an astounding $93.1 billion. Coca-Cola's annualized dividend of $2.04 per share, translating to a forward yield of 2.89%, easily tops the SPDR S&P 500 ETF's (SPY) 1.21%. Coca-Cola unveiled its Q1 earnings results on April 29, proving once again that its 'all-weather strategy' is more than just a catchphrase. Revenue dipped 2% year over year to $11.1 billion, mostly due to currency headwinds and changes in how it reports its bottling biz, but its bottom line still sparkled. EPS rose 5% to $0.77, and comparable EPS edged up 1% to $0.73, beating expectations. Coca-Cola's superpower is still its global reach. Looking ahead, Coca-Cola isn't backing down. The company reaffirmed its full-year 2025 outlook, targeting organic revenue growth of 5% to 6%, despite a 2% to 3% currency drag. Comparable currency-neutral EPS for 2025 is expected to increase 7% to 9% year over year. This outlook shows Coca-Cola's steady hand in stormy markets. Plus, management envisions an adjusted free cash flow of $9.5 billion for fiscal 2025, including $11.7 billion in cash flow from operations. Analysts are buying the story, forecasting $2.96 EPS in fiscal 2025, up 2.8% year over year, with the next year's bottom line anticipated to grow by another 8.1% annually to $3.20 per share. Overall, KO has a solid 'Strong Buy' consensus rating. Out of the 23 analysts in coverage, 21 recommend a 'Strong Buy,' one advises a 'Moderate Buy,' while the remaining one is playing it safe with a 'Hold' rating. KO stock might be gearing up for a refresh. With analysts setting a mean price target of $79.48, the stock could rally as much as 14% from the current price levels. Dividend Aristocrat Stock #2: West Pharmaceutical West Pharmaceutical Services (WST) has quietly become a cornerstone of the global pharmaceutical supply chain. The Pennsylvania-based company engineers sophisticated containment and delivery systems for injectable drugs and healthcare products, serving clients across the Americas, EMEA, and Asia Pacific. The stock has fallen 42% from its 52-week high of $358.52. Over the past year, it has slipped 42%, with a 37% decline on a YTD basis. Despite recent stock struggles, West Pharmaceutical has stayed loyal to its long-term investors. The company has increased dividends for over three decades, and just last month, it declared a payout of $0.21 per share, payable to the shareholders on Aug. 6. Plus, it kept its annual payout at $0.84 with a modest 0.41% yield. While the yield may not grab headlines, the low 12.2% payout ratio underscores West's conservative approach to capital allocation. In Q1 alone, West Pharmaceutical returned $15.2 million in dividends and repurchased over half a million shares for $133.5 million. On April 24, West Pharmaceutical Services delivered a steady yet strategically strong Q1 performance, reporting $698 million in revenue, flat year over year, but still topping expectations by 1.5%. Adjusted EPS landed at $1.45, blowing past estimates by 18.9%, signaling that the company's operational discipline is paying off despite top-line stagnation. Historically, West Pharmaceutical has ranked among the more profitable healthcare players, averaging an operating margin of 22.7% over the past five years. In Q1, adjusted operating profit hit $125 million, with margins climbing to 17.9%, reflecting improved efficiency even in a more complex macro environment. Cash flow also impressed. Operating cash flow rose 9.5% year over year to $129.4 million, while FCF more than doubled to $58.1 million. The company continues to lean into areas of strength, with a clear focus on capital discipline, margin improvement, and stakeholder value. West Pharmaceutical raised its full-year 2025 guidance, estimating net sales to be between $2.945 billion and $2.975 billion, while adjusted EPS is projected between $6.15 and $6.35. Analysts predict the medical device company's EPS to be $6.27 in fiscal 2025, rising by 14.4% annually to $7.17 in fiscal 2026. WST stock has a consensus 'Strong Buy' rating overall. Out of the 12 analysts covering the stock, 11 suggest a 'Strong Buy,' and one recommends a 'Hold.' The mean price target of $293.50 suggests that the stock has upside potential of 42% from current prices.
Globe and Mail
14-05-2025
- Business
- Globe and Mail
5 Highest-Yielding Dividend Aristocrats® That Could Sink or Soar (According to Analysts)
These are the five highest-yielding Dividend Aristocrats®, but are they smart buys or dangerous traps? With volatility and long-term returns in question, discover which dividend stocks may be worth holding forever and which ones investors might want to avoid. *Stock prices used were the market prices of April 30, 2025. The video was published on May 14, 2025. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Dividend Aristocrats® is a registered trademark of Standard & Poor's Financial Services LLC. Should you invest $1,000 in Franklin Resources right now? Before you buy stock in Franklin Resources, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Franklin Resources wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $613,951!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $796,353!* Now, it's worth noting Stock Advisor 's total average return is948% — a market-crushing outperformance compared to170%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 12, 2025 Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amcor Plc and Realty Income. The Motley Fool recommends T. Rowe Price Group. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
Yahoo
10-05-2025
- Business
- Yahoo
Cullen/Frost Bankers, Inc. (CFR): Among the Best Mid-Cap Dividend Aristocrats to Invest in Now
We recently published a list of the 12 Best Mid-Cap Dividend Aristocrats to Invest in Now. In this article, we are going to take a look at where Cullen/Frost Bankers, Inc. (NYSE:CFR) stands against other mid-cap dividend aristocrats. There's a common misunderstanding that dividend payouts are mostly limited to large-cap companies, but mid-cap firms are often just as generous—and notably stable—when it comes to dividends. Recently, mid-cap dividend stocks, which had fallen out of favor, are making a comeback and drawing renewed interest from investment strategists. The MidCap Dividend Aristocrats Index, which includes 53 mid-sized companies that have raised their dividends for at least 15 consecutive years, has declined just 1.2% year-to-date through May 5. In comparison, the broader market has dropped 3.7% over the same period. Notably, these mid-cap companies generate about 82% of their revenue from within the US, significantly higher than the roughly 60% average for broader market firms and 53% for those in the Nasdaq Composite, based on data from S&P Dow Jones Indices and FactSet as of April 30. READ ALSO: Alongside investors, analysts are also recommending that income portfolios include mid-cap companies. According to Simeon Hyman, global investment strategist at ProShares, these stocks can help cushion downside risk amid current market volatility. He noted that this is particularly relevant for investors whose portfolios are heavily weighted toward large-cap growth names like the 'Magnificent Seven' tech giants. Hyman emphasized the importance of diversifying equity exposure across a wider range of asset classes to help manage risk in today's environment. Analysts are leaning toward mid-cap dividend stocks largely because they appear undervalued. As of April 30, the MidCap Dividend Aristocrats Index had a price-to-earnings (P/E) ratio of 17.87, which is significantly lower than the P/E ratios of the broader market and the Nasdaq. Larry Adam, chief investment officer at Raymond James, made the following comment about this: 'Now is the time for bargain-hunting since midcap dividend stocks are trading at historically low valuations relative to large-cap stocks. They could be the sweet spot for investors when you consider they are more insulated from tariff exposure and are expected to outpace the earnings growth of large-caps this year.' According to analysts, instead of picking individual mid-cap dividend stocks, investors should consider exchange-traded funds (ETFs) as an alternative. These funds offer tax efficiency and diversification across multiple industries and typically come with low expense ratios. For instance, the WisdomTree U.S. MidCap Dividend ETF (DON), which manages $3.47 billion in assets, posted a year-to-date return of -6.47% through April 30, with a 12-month return of 4.72% and a 12-month yield of 2.54%. Its expense ratio stands at 0.38%. Meanwhile, the ProShares S&P MidCap Dividend Aristocrats ETF (REGL), with $1.69 billion in assets, returned -1.88% so far this year, delivered a 6.96% one-year return, and yields 2.60% over 12 months. Its expense ratio is 0.40%, according to Morningstar Direct. Though both ETFs are showing negative returns for the year, their dividend payouts help cushion losses. Financial advisers often recommend reinvesting those dividends rather than withdrawing the cash, as this approach can build wealth over time by acquiring more shares while prices remain subdued. A customer tapping their debit card at an ATM, making a secure transaction. For this list, we scanned the holdings of MidCap 400 Dividend Aristocrats, which tracks the performance of mid-sized companies within the MidCap 400 index that have maintained a consistent track record of increasing dividends annually for at least 15 years. From the index, we picked 12 dividend stocks that have garnered the most attention from hedge fund investors by the conclusion of Q4 2024, using data from Insider Monkey's database. The stocks are ranked according to the number of hedge funds having stakes in them. At Insider Monkey, we are obsessed with hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). Number of Hedge Fund Holders: 17 Cullen/Frost Bankers, Inc. (NYSE:CFR) is a Texas-based financial holding company that offers commercial and consumer banking services to its customers. As of March 31, the company has approximately $52 billion in assets. In its latest earnings report, it stated that it expects to open its 199th branch in the Fort Worth area within the next month, followed by the milestone 200th Frost location in Pflugerville, just north of Austin. With these additions, the company noted that it will have grown its total number of locations by over 50% since initiating its organic expansion strategy in December 2018. The stock has surged by over 17% in the past 12 months. In the first quarter of 2025, Cullen/Frost Bankers, Inc. (NYSE:CFR) reported revenue of $560.4 million, which showed a 7.2% growth from the same period last year. The revenue also surpassed analysts' consensus by $18.8 million. Its net interest income came in at $416.2 million, compared with $390 million in the prior-year period. The company's total assets also grew to $41.6 billion, from $40.7 billion in Q1 2024. On May 1, Cullen/Frost Bankers, Inc. (NYSE:CFR) declared a 5.3% hike in its quarterly dividend to $1.00 per share. This marked the company's 32nd consecutive year of dividend growth, which makes CFR one of the best dividend stocks on our list. The stock has a dividend yield of 3.23%, as of May 5. Overall, CFR ranks 12th on our list of the best mid-cap dividend aristocrats to buy now. While we acknowledge the potential of CFR as an investment, our conviction lies in the belief that some deeply undervalued dividend stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for a deeply undervalued dividend stock that is more promising than CFR but that trades at 10 times its earnings and grows its earnings at double digit rates annually, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-05-2025
- Business
- Yahoo
Silgan Holdings Inc. (SLGN): Among the Best Mid-Cap Dividend Aristocrats to Invest in Now
We recently published a list of the 12 Best Mid-Cap Dividend Aristocrats to Invest in Now. In this article, we are going to take a look at where Silgan Holdings Inc. (NYSE:SLGN) stands against other mid-cap dividend aristocrats. There's a common misunderstanding that dividend payouts are mostly limited to large-cap companies, but mid-cap firms are often just as generous—and notably stable—when it comes to dividends. Recently, mid-cap dividend stocks, which had fallen out of favor, are making a comeback and drawing renewed interest from investment strategists. The MidCap Dividend Aristocrats Index, which includes 53 mid-sized companies that have raised their dividends for at least 15 consecutive years, has declined just 1.2% year-to-date through May 5. In comparison, the broader market has dropped 3.7% over the same period. Notably, these mid-cap companies generate about 82% of their revenue from within the US, significantly higher than the roughly 60% average for broader market firms and 53% for those in the Nasdaq Composite, based on data from S&P Dow Jones Indices and FactSet as of April 30. READ ALSO: Alongside investors, analysts are also recommending that income portfolios include mid-cap companies. According to Simeon Hyman, global investment strategist at ProShares, these stocks can help cushion downside risk amid current market volatility. He noted that this is particularly relevant for investors whose portfolios are heavily weighted toward large-cap growth names like the 'Magnificent Seven' tech giants. Hyman emphasized the importance of diversifying equity exposure across a wider range of asset classes to help manage risk in today's environment. Analysts are leaning toward mid-cap dividend stocks largely because they appear undervalued. As of April 30, the MidCap Dividend Aristocrats Index had a price-to-earnings (P/E) ratio of 17.87, which is significantly lower than the P/E ratios of the broader market and the Nasdaq. Larry Adam, chief investment officer at Raymond James, made the following comment about this: 'Now is the time for bargain-hunting since midcap dividend stocks are trading at historically low valuations relative to large-cap stocks. They could be the sweet spot for investors when you consider they are more insulated from tariff exposure and are expected to outpace the earnings growth of large-caps this year.' According to analysts, instead of picking individual mid-cap dividend stocks, investors should consider exchange-traded funds (ETFs) as an alternative. These funds offer tax efficiency and diversification across multiple industries and typically come with low expense ratios. For instance, the WisdomTree U.S. MidCap Dividend ETF (DON), which manages $3.47 billion in assets, posted a year-to-date return of -6.47% through April 30, with a 12-month return of 4.72% and a 12-month yield of 2.54%. Its expense ratio stands at 0.38%. Meanwhile, the ProShares S&P MidCap Dividend Aristocrats ETF (REGL), with $1.69 billion in assets, returned -1.88% so far this year, delivered a 6.96% one-year return, and yields 2.60% over 12 months. Its expense ratio is 0.40%, according to Morningstar Direct. Though both ETFs are showing negative returns for the year, their dividend payouts help cushion losses. Financial advisers often recommend reinvesting those dividends rather than withdrawing the cash, as this approach can build wealth over time by acquiring more shares while prices remain subdued. An industrial robotic arm automating the production of metal containers. For this list, we scanned the holdings of MidCap 400 Dividend Aristocrats, which tracks the performance of mid-sized companies within the MidCap 400 index that have maintained a consistent track record of increasing dividends annually for at least 15 years. From the index, we picked 12 dividend stocks that have garnered the most attention from hedge fund investors by the conclusion of Q4 2024, using data from Insider Monkey's database. The stocks are ranked according to the number of hedge funds having stakes in them. At Insider Monkey, we are obsessed with hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). Number of Hedge Fund Holders: 21 Silgan Holdings Inc. (NYSE:SLGN) is an American manufacturing company that specializes in packaging for consumer goods. The stock is generating solid returns this year, surging by nearly 7% since the start of 2025, while its 12-month returns came in at nearly 17%. Over the years, the company has grown into a leading global supplier of sustainable rigid packaging for consumer products, operating 107 manufacturing facilities across four continents. Silgan Holdings Inc. (NYSE:SLGN) reported $1.47 billion in revenue in the first quarter of 2025, up by over 11.3% from the same period last year. The company's net income for the quarter came in at $68 million, up from $55.2 million in the prior-year period. Its adjusted earnings per share rose by 19%, a figure that came in near the upper end of its projected range for the first quarter. This performance was attributed to volume growth, strong operational execution across all segments, solid contributions from the Weener acquisition, and ongoing progress in its cost reduction efforts. Silgan Holdings Inc. (NYSE:SLGN)'s cash position also remained strong as it ended the quarter with $353 million available in cash and cash equivalents. The company reaffirmed its projected free cash flow for 2025 at around $450 million, representing a 15% increase over the $391.3 million reported in 2024. Due to this cash position, the company managed to grow its dividend for 21 years in a row. Currently, it offers a quarterly dividend of $0.20 per share and has a dividend yield of 1.47%, as of May 5. Overall, SLGN ranks 11th on our list of the best mid-cap dividend aristocrats to buy now. While we acknowledge the potential of SLGN as an investment, our conviction lies in the belief that some deeply undervalued dividend stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for a deeply undervalued dividend stock that is more promising than SLGN but that trades at 10 times its earnings and grows its earnings at double digit rates annually, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
